CO6670522A2 - Conjugados de anticuerpos multifuncionales de anticuerpos anti-igf1r, derivados de los mismos y composiciones que los contienen - Google Patents
Conjugados de anticuerpos multifuncionales de anticuerpos anti-igf1r, derivados de los mismos y composiciones que los contienenInfo
- Publication number
- CO6670522A2 CO6670522A2 CO13004943A CO13004943A CO6670522A2 CO 6670522 A2 CO6670522 A2 CO 6670522A2 CO 13004943 A CO13004943 A CO 13004943A CO 13004943 A CO13004943 A CO 13004943A CO 6670522 A2 CO6670522 A2 CO 6670522A2
- Authority
- CO
- Colombia
- Prior art keywords
- derivatives
- antibody
- compositions containing
- antibody conjugates
- multifunctional antibody
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36350710P | 2010-07-12 | 2010-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6670522A2 true CO6670522A2 (es) | 2013-05-15 |
Family
ID=44630490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13004943A CO6670522A2 (es) | 2010-07-12 | 2013-01-11 | Conjugados de anticuerpos multifuncionales de anticuerpos anti-igf1r, derivados de los mismos y composiciones que los contienen |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8741291B2 (OSRAM) |
| EP (1) | EP2593142B8 (OSRAM) |
| JP (2) | JP5913307B2 (OSRAM) |
| KR (1) | KR20130050966A (OSRAM) |
| CN (1) | CN103096933A (OSRAM) |
| AR (1) | AR082205A1 (OSRAM) |
| AU (1) | AU2011277999A1 (OSRAM) |
| BR (1) | BR112013000951A2 (OSRAM) |
| CA (1) | CA2804185C (OSRAM) |
| CO (1) | CO6670522A2 (OSRAM) |
| ES (1) | ES2704223T3 (OSRAM) |
| MX (1) | MX2013000491A (OSRAM) |
| PE (1) | PE20130643A1 (OSRAM) |
| PH (1) | PH12013500070A1 (OSRAM) |
| RU (1) | RU2012157167A (OSRAM) |
| SG (1) | SG186451A1 (OSRAM) |
| TW (1) | TWI432213B (OSRAM) |
| WO (1) | WO2012007896A1 (OSRAM) |
| ZA (1) | ZA201300161B (OSRAM) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20140260A1 (es) * | 2010-11-05 | 2014-03-19 | Pfizer | Compuestos antidiabeticos |
| BR112013032928A2 (pt) * | 2011-06-21 | 2017-01-24 | Immunogen Inc | "derivados de maitansinoide com ligante de peptídeo e conjugados dos mesmos, composição farmacêutica que os compreende e uso dos mesmos" |
| WO2013072813A2 (en) | 2011-11-17 | 2013-05-23 | Pfizer Inc. | Cytotoxic peptides and antibody drug conjugates thereof |
| EP3447071A1 (en) | 2012-01-09 | 2019-02-27 | Pfizer Healthcare Ireland | Mutant antibodies and conjugation thereof |
| KR102237639B1 (ko) | 2012-10-11 | 2021-04-07 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트 |
| ES2782248T3 (es) | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila |
| AU2013343111A1 (en) | 2012-11-07 | 2015-05-14 | Pfizer Inc. | Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates |
| MX2015005810A (es) | 2012-11-07 | 2015-09-23 | Pfizer | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco. |
| RU2670943C9 (ru) | 2012-11-08 | 2018-11-26 | Илэвэн Байотерапьютикс, Инк. | Антагонисты ил-6 и их применение |
| JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
| WO2015057066A1 (en) * | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| WO2015057063A1 (en) * | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| IL320281A (en) | 2013-12-25 | 2025-06-01 | Daiichi Sankyo Co Ltd | Anti-trop2 antibodies and methods for producing same |
| PH12020552271A1 (en) | 2014-01-31 | 2022-05-02 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
| DK3129063T3 (da) | 2014-04-10 | 2021-04-06 | Daiichi Sankyo Co Ltd | Anti-her3-antistof-lægemiddelkonjugat |
| EP3130608B1 (en) | 2014-04-10 | 2019-09-04 | Daiichi Sankyo Co., Ltd. | (anti-her2 antibody)-drug conjugate |
| MY185114A (en) | 2014-11-07 | 2021-04-30 | Sesen Bio Inc | Improved il-6 antibodies |
| CN107847588B (zh) * | 2015-05-20 | 2021-12-28 | 免疫功坊股份有限公司 | 具有靶向部分及效应部分的分子构建体及其应用 |
| PE20180498A1 (es) * | 2015-06-19 | 2018-03-09 | Eisai Randd Man Co Ltd | Inmunoglobulinas conjugadas en cys80 |
| US11173213B2 (en) | 2015-06-29 | 2021-11-16 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| CA2996652A1 (en) * | 2015-09-01 | 2017-03-09 | Immunwork Inc. | Molecular constructs for preventing the formation of blood clot and/or treating thrombosis |
| JP6990650B2 (ja) * | 2015-09-17 | 2022-03-04 | ザ スクリプス リサーチ インスティテュート | 二重可変ドメインイムノコンジュゲートおよびその用途 |
| UY36961A (es) * | 2015-10-23 | 2017-05-31 | Sorrento Therapeutics Inc | Receptores celulares universales programables y métodos para usar los mismos |
| US20220008553A1 (en) * | 2015-11-23 | 2022-01-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| CN107029244B (zh) * | 2016-02-04 | 2021-04-27 | 浙江昭华生物医药有限公司 | 抗her2抗体-药物偶联物及其应用 |
| JP2019518017A (ja) | 2016-02-09 | 2019-06-27 | アレクサンダー・クランツ | トレースレス親和性標識を使用したタンパク質の部位選択的官能化 |
| CN108718522A (zh) * | 2016-02-23 | 2018-10-30 | 赛森生物股份有限公司 | Il-6拮抗剂制剂及其用途 |
| CA3029902A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| CN110049779A (zh) | 2016-12-12 | 2019-07-23 | 第一三共株式会社 | 抗体-药物缀合物和免疫检查点抑制剂的组合 |
| EP3572428A4 (en) | 2017-01-17 | 2020-12-30 | Daiichi Sankyo Company, Limited | ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20 |
| KR20190111086A (ko) | 2017-01-24 | 2019-10-01 | 화이자 인코포레이티드 | 칼리키아마이신 유도체 및 이의 항체 약물 접합체 |
| TW202530271A (zh) | 2017-05-15 | 2025-08-01 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| KR20250084239A (ko) | 2017-08-31 | 2025-06-10 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 개량 제조 방법 |
| CA3074208C (en) | 2017-08-31 | 2023-10-03 | Daiichi Sankyo Company, Limited | Novel method for producing antibody-drug conjugate |
| WO2019090242A1 (en) * | 2017-11-04 | 2019-05-09 | Advanced Proteome Therapeutics Inc. | Composition and method for modifying polypeptides |
| EP3737699A1 (en) | 2018-01-12 | 2020-11-18 | Amgen Inc. | Pac1 antibodies and uses thereof |
| US12479926B2 (en) | 2018-05-18 | 2025-11-25 | Daiichi Sankyo Co., Ltd. | Anti-MUC1 antibody-drug conjugate |
| WO2020022475A1 (ja) | 2018-07-27 | 2020-01-30 | 第一三共株式会社 | 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質 |
| US12220604B2 (en) | 2018-07-31 | 2025-02-11 | Daiichi Sankyo Company, Limited | Treatment of metastatic brain tumor by administration of an antibody-drug conjugate |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100934PA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| CN113330029A (zh) * | 2019-08-19 | 2021-08-31 | 沈阳药科大学 | 抗体的突变体及其应用 |
| US20220347312A1 (en) | 2019-09-04 | 2022-11-03 | Bolt Biotherapeutics, Inc. | Immunoconjugate Synthesis Method |
| AU2022309028A1 (en) | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| EP4370157A1 (en) | 2021-07-14 | 2024-05-22 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| MX2024005332A (es) * | 2021-11-01 | 2024-05-20 | Dyne Therapeutics Inc | Complejos dirigidos al musculo para el tratamiento de distrofinopatias. |
| EP4508091A1 (en) * | 2022-04-15 | 2025-02-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| AU2023350248A1 (en) | 2022-09-30 | 2025-04-17 | Shanghai De Novo Pharmatech Co., Ltd. | Benzazepine derivative, conjugate containing same, and use thereof |
| AU2024229817A1 (en) | 2023-02-28 | 2025-08-14 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Chemical coupling linker and use thereof |
| CN118805740B (zh) * | 2024-08-07 | 2025-12-19 | 中国中医科学院中药研究所 | 一种人呼吸道合胞病毒感染小鼠重症肺炎动物模型的构建方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| EP1228087B1 (en) | 1999-10-08 | 2010-06-09 | The Scripps Research Institute | Antibody catalysis of enantio- and diastereo-selective aldol reactions |
| MA26040A1 (fr) | 2001-01-05 | 2004-04-01 | Pfizer | Des anticorps pour recepteur i de facteur de croissance insulinique |
| EP1443963B1 (en) | 2001-10-22 | 2014-05-21 | The Scripps Research Institute | Antibody targeting compounds |
| US7217845B2 (en) * | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| JP4638870B2 (ja) | 2003-08-13 | 2011-02-23 | ファイザー・プロダクツ・インク | 修飾ヒトｉｇｆ−１ｒ抗体 |
| CA2598833A1 (en) | 2005-03-03 | 2006-09-08 | Curt W. Bradshaw | Anti-angiogenic compounds |
| NZ576751A (en) | 2006-11-10 | 2011-10-28 | Covx Technologies Ireland Ltd | Anti-angiogenic compounds |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| EP2190480A4 (en) | 2007-08-28 | 2013-01-23 | Biogen Idec Inc | ANTI-IGR-1R ANTIBODIES AND ITS USES |
| CN115043946A (zh) | 2008-01-03 | 2022-09-13 | 斯克里普斯研究院 | 通过模块识别结构域的抗体靶向 |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
-
2011
- 2011-07-11 PE PE2013000052A patent/PE20130643A1/es not_active Application Discontinuation
- 2011-07-11 SG SG2012094983A patent/SG186451A1/en unknown
- 2011-07-11 AR ARP110102486A patent/AR082205A1/es not_active Application Discontinuation
- 2011-07-11 WO PCT/IB2011/053092 patent/WO2012007896A1/en not_active Ceased
- 2011-07-11 JP JP2013519199A patent/JP5913307B2/ja active Active
- 2011-07-11 RU RU2012157167/10A patent/RU2012157167A/ru not_active Application Discontinuation
- 2011-07-11 CA CA2804185A patent/CA2804185C/en active Active
- 2011-07-11 ES ES11745833T patent/ES2704223T3/es active Active
- 2011-07-11 AU AU2011277999A patent/AU2011277999A1/en not_active Abandoned
- 2011-07-11 MX MX2013000491A patent/MX2013000491A/es unknown
- 2011-07-11 EP EP11745833.1A patent/EP2593142B8/en active Active
- 2011-07-11 BR BR112013000951A patent/BR112013000951A2/pt not_active Application Discontinuation
- 2011-07-11 CN CN2011800438472A patent/CN103096933A/zh active Pending
- 2011-07-11 KR KR1020137003413A patent/KR20130050966A/ko not_active Ceased
- 2011-07-11 PH PH1/2013/500070A patent/PH12013500070A1/en unknown
- 2011-07-12 TW TW100124612A patent/TWI432213B/zh not_active IP Right Cessation
- 2011-11-28 US US13/305,354 patent/US8741291B2/en active Active
-
2013
- 2013-01-07 ZA ZA2013/00161A patent/ZA201300161B/en unknown
- 2013-01-11 CO CO13004943A patent/CO6670522A2/es unknown
-
2015
- 2015-12-21 JP JP2015248537A patent/JP6339995B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130050966A (ko) | 2013-05-16 |
| JP5913307B2 (ja) | 2016-04-27 |
| CA2804185A1 (en) | 2012-01-19 |
| AR082205A1 (es) | 2012-11-21 |
| CN103096933A (zh) | 2013-05-08 |
| PE20130643A1 (es) | 2013-06-07 |
| ES2704223T3 (es) | 2019-03-15 |
| TW201216986A (en) | 2012-05-01 |
| EP2593142B1 (en) | 2018-10-10 |
| AU2011277999A1 (en) | 2013-01-10 |
| JP6339995B2 (ja) | 2018-06-06 |
| ZA201300161B (en) | 2013-09-25 |
| CA2804185C (en) | 2017-03-21 |
| TWI432213B (zh) | 2014-04-01 |
| EP2593142B8 (en) | 2018-12-26 |
| EP2593142A1 (en) | 2013-05-22 |
| US20120201809A1 (en) | 2012-08-09 |
| RU2012157167A (ru) | 2014-08-20 |
| WO2012007896A1 (en) | 2012-01-19 |
| SG186451A1 (en) | 2013-01-30 |
| MX2013000491A (es) | 2013-02-26 |
| US8741291B2 (en) | 2014-06-03 |
| JP2016094455A (ja) | 2016-05-26 |
| BR112013000951A2 (pt) | 2016-05-17 |
| JP2013534535A (ja) | 2013-09-05 |
| PH12013500070A1 (en) | 2017-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6670522A2 (es) | Conjugados de anticuerpos multifuncionales de anticuerpos anti-igf1r, derivados de los mismos y composiciones que los contienen | |
| ECSP10010724A (es) | Compuestos de isoindol 5-sustituidos | |
| EA201490095A1 (ru) | Новые производные майтанзиноида с пептидным линкером и их конъюгаты | |
| EA201190021A1 (ru) | Модуляторы toll-подобных рецепторов | |
| GT201300025A (es) | Derivados anticancerosos, su preparación y su aplicación en terapeútica | |
| MX2019009428A (es) | Conjugados de pirrolobenzodiazepinas y anticuerpos. | |
| PE20191235A1 (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente | |
| CY1115932T1 (el) | Σκευασμα αντισωματος | |
| CR20150625A (es) | Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas | |
| CR20140368A (es) | Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036) | |
| CY1119826T1 (el) | Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη | |
| CO6480927A2 (es) | Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17. | |
| MX347240B (es) | Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos. | |
| PE20121534A1 (es) | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuerpo | |
| MA38647B1 (fr) | Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x | |
| CR20110268A (es) | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1 | |
| EA202090148A1 (ru) | Пирролобензодиазепиновые конъюгаты | |
| CY1115919T1 (el) | Ενωσεις ενεργοποιησης τελομερασης και μεθοδοι χρησης αυτων | |
| GT200500156A (es) | Derivados de acido carboxilico de bencimidazolona | |
| DOP2008000089A (es) | 18-metil-19-nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen | |
| MX2018009585A (es) | Conjugados de pirrolobenzodiazepina. | |
| HN2010001537A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| DOP2012000078A (es) | Derivados de espirolactama y usos de los mismos | |
| CR9391A (es) | Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| GB202004263D0 (en) | Antibody conjugate |